Moreover, polymorphisms in estrogen metabolism-related genes, such as PDSS1, CYP19A1, CYP1A1, and CYP1B1, have been associated with varied efficacy of raloxifene, a selective estrogen receptor modulator frequently prescribed for postmenopausal osteoporosis [102]. Here, CYP1B1 is linked to postmenopausal osteoporosis.